Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) is anticipated to release its Q2 2026 resultson Monday, August 17th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 20, 2026 at 8:30 AM ET.
Brainstorm Cell Therapeutics Stock Performance
Shares of Brainstorm Cell Therapeutics stock opened at $0.79 on Monday. The firm has a market capitalization of $8.76 million, a PE ratio of -0.23 and a beta of 0.23. The business’s 50-day moving average price is $0.93 and its 200-day moving average price is $0.80. Brainstorm Cell Therapeutics has a 12 month low of $0.46 and a 12 month high of $1.69.
About Brainstorm Cell Therapeutics
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
Read More
- Five stocks we like better than Brainstorm Cell Therapeutics
- Albemarle’s Blowout Quarter Shows Why Lithium Still Matters
- Can DICK’S Turn Foot Locker Into a Winner?
- Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue
- Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
